Global Revenue Of Oral Mucositis Drugs Is Nearly 400 Million USD In 2024
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
Oral Mucositis is a disorder in which an individual grows painful lesions of the mucus membranes of the mouth. It is a side effect of cancer treatment and typically increases in harshness as the dose of chemo or radiation therapy increases.
In the last several years, global market of Oral Mucositis Drugs developed rapidly, with an average growth rate of 7.7%. In 2017, global revenue of Oral Mucositis Drugs is nearly 400 million USD.
The classification of Oral Mucositis Drugs includes Mouthwash, Pain?Control?Medication and Other, the sales of Mouthwash are 16.9 million units, with its market share 48.8%. And the sales market share of Pain?Control?Medication is 38% in 2017.
Oral Mucositis Drugs is widely used to Chemotherapy Oral Mucositis and Radiotherapy Oral Mucositis. The most proportion of Oral Mucositis Drugs is to Radiotherapy Oral Mucositis, and the proportion is about 69.6% in 2017.
North America region is the largest supplier of Oral Mucositis Drugs, with a production market share nearly 53.6% in 2017. Europe is the second largest supplier of Oral Mucositis Drugs, enjoying production market share nearly 33.2% in 2017.
North America is the largest sales place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest sales place with the sales market share of 26.9% in 2017. China is an important market of Oral Mucositis Drugs in Asia, accounting for 7.6% sales market share of global market.
3M Healthcare, GSK, Pfizer, Colgate-Palmolive, Biovitrum are the leaders of the industry, and hold key technologies and patents. Other manufactures’ products are used to meet local demand. With further expanding market, there will be more players in the future.